Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Hosted on MSN1d
AstraZeneca Expands U.S. Investment Plan
AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
Bisnow13h
AstraZeneca To Invest $3.5B To Grow U.S. Footprint
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
STAT1d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
FiercePharma1d
AstraZeneca and Merck's Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
AstraZeneca Director Bolsters Stake with Share Purchase
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...
The Financial Express24m
AstraZeneca India partners with IAP to raise awareness on RSV in India
RSV symptoms include cough, fever, running nose, irritability, reduced activity, and pauses in breathing. Severe cases can lead to bronchiolitis or pneumonia, requiring hospitalisation.
AstraZeneca slumps as Q2 PAT slides 27% YoY to Rs 38 cr
AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24.
Business Insider19h
AstraZeneca: Strong Q3 Growth and Strategic Moves Justify Buy Rating
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...